CN116554079B - 一种组蛋白去乙酰化酶抑制剂及用途 - Google Patents
一种组蛋白去乙酰化酶抑制剂及用途 Download PDFInfo
- Publication number
- CN116554079B CN116554079B CN202310842593.5A CN202310842593A CN116554079B CN 116554079 B CN116554079 B CN 116554079B CN 202310842593 A CN202310842593 A CN 202310842593A CN 116554079 B CN116554079 B CN 116554079B
- Authority
- CN
- China
- Prior art keywords
- diketopyrrolopyrrole
- hydroxyheptanamide
- carbon atoms
- benzylidene
- dioxopyrrolidinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003276 histone deacetylase inhibitor Substances 0.000 title abstract description 17
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title abstract description 11
- 102000003964 Histone deacetylase Human genes 0.000 claims abstract description 24
- 108090000353 Histone deacetylase Proteins 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- -1 hydroxy, mercapto Chemical class 0.000 claims description 156
- 150000001875 compounds Chemical class 0.000 claims description 135
- 125000004432 carbon atom Chemical group C* 0.000 claims description 52
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- 125000001188 haloalkyl group Chemical group 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000004414 alkyl thio group Chemical group 0.000 claims description 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 14
- 125000004122 cyclic group Chemical group 0.000 claims description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000003282 alkyl amino group Chemical group 0.000 claims description 10
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- AEDIXYWIVPYNBI-UHFFFAOYSA-N heptanamide Chemical compound CCCCCCC(N)=O AEDIXYWIVPYNBI-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 claims description 7
- JGSLKNWXPRDWBA-UHFFFAOYSA-N 2-methylidene-1h-pyridine Chemical compound C=C1NC=CC=C1 JGSLKNWXPRDWBA-UHFFFAOYSA-N 0.000 claims description 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 6
- 229910052805 deuterium Inorganic materials 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 150000001721 carbon Chemical group 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 150000003254 radicals Chemical class 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims description 3
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims description 3
- 125000001318 4-trifluoromethylbenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(F)(F)F 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 201000010175 gallbladder cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000007538 neurilemmoma Diseases 0.000 claims description 3
- 125000006504 o-cyanobenzyl group Chemical group [H]C1=C([H])C(C#N)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- LTHCSWBWNVGEFE-UHFFFAOYSA-N octanamide Chemical compound CCCCCCCC(N)=O LTHCSWBWNVGEFE-UHFFFAOYSA-N 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 206010039667 schwannoma Diseases 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical group 0.000 claims 19
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 10
- 239000003112 inhibitor Substances 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 5
- 230000005918 in vitro anti-tumor Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 138
- 230000015572 biosynthetic process Effects 0.000 description 123
- 238000003786 synthesis reaction Methods 0.000 description 123
- 239000007858 starting material Substances 0.000 description 61
- 239000007787 solid Substances 0.000 description 44
- 238000005160 1H NMR spectroscopy Methods 0.000 description 42
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 41
- GNCLPIAYAPQPOU-UHFFFAOYSA-N ethyl 2-bromoheptanoate Chemical compound CCCCCC(Br)C(=O)OCC GNCLPIAYAPQPOU-UHFFFAOYSA-N 0.000 description 29
- 125000001183 hydrocarbyl group Chemical group 0.000 description 20
- 238000000034 method Methods 0.000 description 18
- FLHBCOKNLNJEHU-RMKNXTFCSA-N (3e)-3-benzylidenepyrrolidine-2,5-dione Chemical compound O=C1NC(=O)C\C1=C/C1=CC=CC=C1 FLHBCOKNLNJEHU-RMKNXTFCSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 8
- TVQGDYNRXLTQAP-UHFFFAOYSA-N ethyl heptanoate Chemical compound CCCCCCC(=O)OCC TVQGDYNRXLTQAP-UHFFFAOYSA-N 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- KOUAQOCYMAENKN-UHFFFAOYSA-N ethyl 2-bromohexanoate Chemical compound CCCCC(Br)C(=O)OCC KOUAQOCYMAENKN-UHFFFAOYSA-N 0.000 description 6
- PQMCFTMVQORYJC-WDSKDSINSA-N (1s,2s)-2-aminocyclohexan-1-ol Chemical compound N[C@H]1CCCC[C@@H]1O PQMCFTMVQORYJC-WDSKDSINSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 102000003893 Histone acetyltransferases Human genes 0.000 description 4
- 108090000246 Histone acetyltransferases Proteins 0.000 description 4
- 150000004985 diamines Chemical class 0.000 description 4
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- XIMFCGSNSKXPBO-UHFFFAOYSA-N ethyl 2-bromobutanoate Chemical compound CCOC(=O)C(Br)CC XIMFCGSNSKXPBO-UHFFFAOYSA-N 0.000 description 3
- ORSIRXYHFPHWTN-UHFFFAOYSA-N ethyl 2-bromopentanoate Chemical compound CCCC(Br)C(=O)OCC ORSIRXYHFPHWTN-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PKZJLOCLABXVMC-UHFFFAOYSA-N 2-Methoxybenzaldehyde Chemical compound COC1=CC=CC=C1C=O PKZJLOCLABXVMC-UHFFFAOYSA-N 0.000 description 2
- 239000001431 2-methylbenzaldehyde Substances 0.000 description 2
- OPHQOIGEOHXOGX-UHFFFAOYSA-N 3,4,5-trimethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1OC OPHQOIGEOHXOGX-UHFFFAOYSA-N 0.000 description 2
- WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- WTWBUQJHJGUZCY-UHFFFAOYSA-N cuminaldehyde Chemical compound CC(C)C1=CC=C(C=O)C=C1 WTWBUQJHJGUZCY-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- JIQJOKSCSVMZAN-UHFFFAOYSA-N ethyl 2-bromooctanoate Chemical compound CCCCCCC(Br)C(=O)OCC JIQJOKSCSVMZAN-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- BTFQKIATRPGRBS-UHFFFAOYSA-N o-tolualdehyde Chemical compound CC1=CC=CC=C1C=O BTFQKIATRPGRBS-UHFFFAOYSA-N 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LFDXAZXNBRTFPS-WEVVVXLNSA-N (3e)-3-[(3,4-dimethoxyphenyl)methylidene]pyrrolidine-2,5-dione Chemical compound C1=C(OC)C(OC)=CC=C1\C=C/1C(=O)NC(=O)C\1 LFDXAZXNBRTFPS-WEVVVXLNSA-N 0.000 description 1
- OBDRDBCOPKQBLM-FPYGCLRLSA-N (3e)-3-[(4-hydroxy-3,5-dimethoxyphenyl)methylidene]pyrrolidine-2,5-dione Chemical compound COC1=C(O)C(OC)=CC(\C=C/2C(NC(=O)C\2)=O)=C1 OBDRDBCOPKQBLM-FPYGCLRLSA-N 0.000 description 1
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 1
- DUVJMSPTZMCSTQ-UHFFFAOYSA-N 2-ethoxybenzaldehyde Chemical compound CCOC1=CC=CC=C1C=O DUVJMSPTZMCSTQ-UHFFFAOYSA-N 0.000 description 1
- QVTPWONEVZJCCS-UHFFFAOYSA-N 2-formylbenzonitrile Chemical compound O=CC1=CC=CC=C1C#N QVTPWONEVZJCCS-UHFFFAOYSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- PJKVFARRVXDXAD-UHFFFAOYSA-N 2-naphthaldehyde Chemical compound C1=CC=CC2=CC(C=O)=CC=C21 PJKVFARRVXDXAD-UHFFFAOYSA-N 0.000 description 1
- ZWUSBSHBFFPRNE-UHFFFAOYSA-N 3,4-dichlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1Cl ZWUSBSHBFFPRNE-UHFFFAOYSA-N 0.000 description 1
- UCZKZZFMEDFZCD-UHFFFAOYSA-N 3-[(2-hydroxyphenyl)methylidene]pyrrolidine-2,5-dione Chemical compound OC1=CC=CC=C1C=C1C(=O)NC(=O)C1 UCZKZZFMEDFZCD-UHFFFAOYSA-N 0.000 description 1
- HMRMXHNSJSQSKA-UHFFFAOYSA-N 3-[(4-methoxyphenyl)methylidene]pyrrolidine-2,5-dione Chemical compound C1=CC(OC)=CC=C1C=C1C(=O)NC(=O)C1 HMRMXHNSJSQSKA-UHFFFAOYSA-N 0.000 description 1
- DOCUELVWOMJVIL-UHFFFAOYSA-N 3-[(4-methylphenyl)methylidene]pyrrolidine-2,5-dione Chemical compound C1=CC(C)=CC=C1C=C1C(=O)NC(=O)C1 DOCUELVWOMJVIL-UHFFFAOYSA-N 0.000 description 1
- SUISZCALMBHJQX-UHFFFAOYSA-N 3-bromobenzaldehyde Chemical compound BrC1=CC=CC(C=O)=C1 SUISZCALMBHJQX-UHFFFAOYSA-N 0.000 description 1
- SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 1
- PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 description 1
- RZODAQZAFOBFLS-UHFFFAOYSA-N 3-iodobenzaldehyde Chemical compound IC1=CC=CC(C=O)=C1 RZODAQZAFOBFLS-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 description 1
- YMXQYZABFWVXEK-UHFFFAOYSA-N 4-bromo-2-methoxybenzaldehyde Chemical compound COC1=CC(Br)=CC=C1C=O YMXQYZABFWVXEK-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- 125000002528 4-isopropyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IJIBRSFAXRFPPN-UHFFFAOYSA-N 5-bromo-2-methoxybenzaldehyde Chemical compound COC1=CC=C(Br)C=C1C=O IJIBRSFAXRFPPN-UHFFFAOYSA-N 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- TWQLMAJROCNXEA-UHFFFAOYSA-N ethyl 4-(bromomethyl)benzoate Chemical compound CCOC(=O)C1=CC=C(CBr)C=C1 TWQLMAJROCNXEA-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
- 108010091666 romidepsin Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- KCDXJAYRVLXPFO-UHFFFAOYSA-N syringaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1O KCDXJAYRVLXPFO-UHFFFAOYSA-N 0.000 description 1
- COBXDAOIDYGHGK-UHFFFAOYSA-N syringaldehyde Natural products COC1=CC=C(C=O)C(OC)=C1O COBXDAOIDYGHGK-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种组蛋白去乙酰化酶抑制剂及用途,属于医药化学领域。本发明通过引入丁二酰亚胺片段得到一类结构新型、高效的HDACs抑制剂。其有益效果是:对HDACs具有优良的抑制活性并且还具有优良的体外抗肿瘤活性,为HDAC抑制剂在实体瘤中的应用/或治疗与组蛋白去乙酰化酶活性失控有关的疾病提供新的途径。
Description
技术领域
本发明涉及一种组蛋白去乙酰化酶抑制剂及用途,属于化学技术领域。
背景技术
表观遗传异常与人类多种疾病的发生密切相关,主要由于基因缺陷引起的表观遗传蛋白功能失调导致。组蛋白去乙酰化酶(HDAC)和组蛋白乙酰转移酶(HATs)是一组生物学功能相反的酶,动态调控着组蛋白的去乙酰化和乙酰化。在正常细胞中,HDAC和HATs能够保持动态平衡,对于基因的正常表达起着关键作用。HDAC和HATs的动态平衡通常以HDAC的生物活性异常增强被打破,进而影响细胞周期和细胞凋亡的相关基因表达异常及相应信号通路的异常。研究表明HDAC的异常表达与癌症、炎症、神经***疾病等多种疾病的发生、发展密切相关。因此,HDAC抑制剂的开发在药物开发领域已引起广泛的兴趣,并表现出广阔的应用前景。迄今为止,美国食品药物管理局先后批准了四种 HDAC抑制剂,伏立诺他、罗米地辛、贝立司他和帕比司他,以及中国食品药品监督管理局批准的西达本胺,主要用于治疗皮肤T细胞淋巴瘤、外周T细胞淋巴瘤、多发性骨髓瘤等血液***癌症。然而,HDAC抑制剂药物面临着重要瓶颈和挑战:当前上市的HDAC抑制剂主要在血液***癌症的治疗上得到成功应用,但对实体瘤的单一治疗效果普遍不佳,如乳腺癌、肾癌、***癌和头颈部癌症等,限制了其在临床上的广泛使用。因此开发结构新型、高效HDAC抑制剂,拓展其在实体瘤中应用,具有迫切的临床需求。
发明内容
本发明的目的是针对现有技术存在的HDAC抑制剂药物对于实体瘤治疗效果不佳的缺陷,开发出一种新的组蛋白去乙酰化酶抑制剂,旨在提供更加高效、安全的HDAC抑制剂,并提高HDAC抑制剂对于实体瘤的治疗效果。
HDAC小分子抑制剂主要由四部分组成:锌离子结合基团(zinc binding group,ZBG)、连接链(linker)、连接单元(connect unit, CU)、帽子基团(Cap)。现有技术对于HDAC小分子抑制剂的研究主要集中在锌离子结合基团和连接单元,大部分HDAC抑制剂的CU往往仅为一个简单的sp2杂化基团,例如酰胺、羰基等。但CU对于分子构象以至于药效、药代动力学性质都有着至关重要的影响。因此本发明目的是提供一类新型、有效的HDACs抑制剂及其药学上可接受的盐。基于该目的,本发明首先提供以下化合物,其通式如下:
,
式中X、Y、Z、M1、M2各自独立地表示碳或者氮原子,
当X、Y、Z、M1、M2为碳原子时,各自独立地任选被R2取代,R2为氢、烷基、氰基、卤素、卤代烷基、羟基、巯基、烷氧基、烷氨基、烷硫基、烷氧基烷基、芳烷基、二芳基烷基、芳基或Het;
M3为碳,可以各自独立地任选被R4、R5取代,R4、R5为氢、氘、烷基、卤代烷基、羟基、巯基、烷氧基、烷氨基、烷硫基、烷氧基烷基、亚甲基、芳烷基、二芳基烷基、芳基或Het;
Q1是选自长度为1-8个碳原子的饱和或不饱和直链或支链烃基,芳基或Het;
R1选自羟基、被一个或多个R3取代的2-氨基苯基,
R3 是氢、烷基、氰基、卤素、卤代烷基、羟基、巯基、烷氧基、烷硫基、烷氧基烷基、芳烷基、芳基或Het;
烷基为具有1-6个碳原子的直链或支链饱和烃基;或为具有3-6个碳原子的环状饱和烃基;或为连接具有1-6个碳原子的直链或支链饱和烃基的具有3-6个碳原子的环状饱和烃基;
烷氧基为具有1-6个碳原子的直链或支链饱和烃基;或为具有3-6个碳原子的环状饱和烃基;或为连接具有1-6个碳原子的直链或支链饱和烃基的具有3-6个碳原子的环状饱和烃基;其中各碳原子任选被氧取代;
烷氨基为具有1-6个碳原子的直链或支链饱和烃基;或为具有3-6个碳原子的环状饱和烃基;或为连接具有1-6个碳原子的直链或支链饱和烃基的具有3-6个碳原子的环状饱和烃基;其中各碳原子任选被NH原子团取代;
烷氧基烷基如上定义的烷氧基与烷基连接;
烯基、炔基为具有1-6个碳原子的直链或支链的含有双键或三键的不饱和烃基;
芳基为选自苯基、萘基、苊基或四氢萘基的碳环,其各自任选被1、2或3个取代基取代,各取代基独立地选自氢、烷基、氰基、卤素、卤代烷基、羟基、巯基、烷氧基、烷硫基、烷氧基烷基、芳烷基、二芳基烷基、芳基或Het ;
芳烷基、二芳基烷基为如上定义的芳基与烷基连接;
Het为选自吡咯基、吡唑基、咪唑基、呋喃基、噻吩基、噁唑基、异噁唑基、噻唑基、异噻唑基、吡啶基、嘧啶基、吡嗪基或哒嗪基的单环杂环;或选自喹啉基、喹喔啉基、吲哚基、苯并咪唑基、苯并噁唑基、苯并异噁唑基、苯并噻唑基、苯并异噻唑基、苯并呋喃基、苯并噻吩基、2, 3-二氢苯并[1,4]二氧杂环己烯基或苯并[1,3]二氧杂环戊烯基的双环杂环;或选自3-6 个碳原子的单环饱和烃基、6-12个碳原子的双环饱和烃基,其中环上的碳原子独立任选地被1-4个O、S、N或NH取代;各单环或双环任选被1、2或3个取代基取代,各取代基独立选自卤素、卤代烷基、羟基、烷基或烷氧基;
卤素为选自氟、氯、溴或碘的取代基;
卤代烷基为具有1-6个碳原子的直链或支链饱和烃基,或为具有3-6个碳原子的环状饱和烃基,或为连接具有1-6个碳原子的直链或支链饱和烃基的具有3-6个碳原子的环状饱和烃基;其中一个或多个碳原子被一个或多个卤原子取代。
本发明进一步选择以下化合物作为HDACs抑制剂:式中X、Y、Z、M1、M2各自独立地表示碳或者氮原子,当X、Y、Z、M1、M2为碳原子时,各自独立地任选被R2取代,R2是氢、烷基、氰基、卤素、卤代烷基、烷氧基、烷硫基、烷氧基烷基;
M3为碳,可以各自独立地任选被R4、R5取代,R4、R5为氢、氘、烷基、卤代烷基、羟基、巯基、烷氧基、烷氨基、烷硫基、烷氧基烷基、亚甲基、芳烷基、二芳基烷基、芳基或Het;
Q1是选自长度为1-8个碳原子的饱和或不饱和直链或支链烃基、芳基;
R1选自羟基、任选被一个或多个R3取代的2-氨基苯基;
R3是氢、烷基、氰基、卤素、卤代烷基、芳基或Het。
本发明进一步选择以下化合物作为HDACs抑制剂:式中X、Y、Z、M1、M2各自独立的表示碳或者氮原子,当X、Y、Z、M1、M2为碳原子时,各自独立地任选被R2取代,R2是氢、烷基、卤素、烷氧基;
M3为碳,可以各自独立地任选被R4、R5取代,R4、R5为氢、氘、烷基、卤代烷基、羟基、巯基、烷氧基、烷氨基、烷硫基、烷氧基烷基、亚甲基、芳烷基、二芳基烷基、芳基或Het;
Q1是选自长度为3-8个碳原子的饱和或不饱和直链或支链烃基、芳基;
R1选自羟基、任选被一个或多个R3取代的2-氨基苯基,
R3是氢、烷基、氰基、卤素、卤代烷基、芳基或Het。
本发明再进一步选择以下化合物作为HDACs抑制剂:
(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基丁酰胺(Ⅰ-1),
(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基戊酰胺(Ⅰ-2),
(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基己酰胺(Ⅰ-3),
(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基庚酰胺(Ⅰ-4),
(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基辛酰胺(Ⅰ-5),
(E)-N-(2-氨基-4-氟苯基)-4-(3-亚苄基-2,5-二酮吡咯烷基)丁酰胺(Ⅰ-6),
(E)-N-(2-氨基-4-氟苯基)-5-(3-亚苄基-2,5-二酮吡咯烷基)戊酰胺(Ⅰ-7),
(E)-N-(2-氨基-4-氟苯基)-6-(3-亚苄基-2,5-二酮吡咯烷基)己酰胺(Ⅰ-8),
(E)-N-(2-氨基-4-氟苯基)-7-(3-亚苄基-2,5-二酮吡咯烷基)庚酰胺(Ⅰ-9),
4-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)丁酰胺(Ⅰ-10),
5-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)戊酰胺(Ⅰ-11),
6-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)己酰胺(Ⅰ-12),
7-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)庚酰胺(Ⅰ-13),
8-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)辛酰胺(Ⅰ-14),
(E)-7-(3-(4-异丙基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-15),
(E)-7-(3-(4-二甲氨基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-16),
(E)-7-(3-(4-三氟甲基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-17),
(E)-7-(3-(4-甲基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-18),
(E)-7-(3-(2-甲基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-19),
(E)-7-(3-(2-氰基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-20),
(E)-7-(3-(2-亚甲基吡啶)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-21),
(E)-7-(3-(2-亚甲基萘基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-22),
(E)-7-(3-(2-亚甲基噻吩基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-23),
(E)-7-(3-(2-氯亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-24),
(E)-7-(3-(3-氯亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-25),
(E)-7-(3-(4-氯亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-26),
(E)-7-(3-(3-溴亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-27),
(E)-7-(3-(3-氟亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-28),
(E)-7-(3-(3-碘亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-29),
(E)-7-(3-(3,4-二氯亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-30),
(E)-7-(3-(2-甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-31),
(E)-7-(3-(3-甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-32),
(E)-7-(3-(4-甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-33),
(E)-7-(3-(3,4-二甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-34),
(E)-7-(3-(3,4,5-三甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-35),
(E)-7-(3-(4-羟基-3,5-二甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-36),
(E)-7-(3-(2-羟基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-37),
(E)-7-(3-(2-乙氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-38),
(E)-7-(3-(5-溴-2-甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-39),
(E)-7-(3-(4-溴-2-甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-40),
(E)-4-((3-亚苄基-2,5-二酮吡咯烷基)甲基)-N-羟基苯甲酰胺(Ⅰ-41)。
上述化合物按以下方法制备:
按上述或类似上述的制备方法制备本发明的化合物,根据取代基的不同和取代基位置的不同选用相应的原料即可。
本发明进一步提供一种药物组合物,其包含以上化合物或其药学上可接受的盐和药学上可接受的载体,其中,以上化合物或其药学上可接受的盐为活性成分。
本发明再进一步提供以上化合物在制备用于预防或治疗与HDACs有关的临床病症的药物中的用途。其中,与HDACs有关的疾病是肺癌、黑色素瘤、肝癌、肾癌、白血病、***癌、甲状腺癌、皮肤病、胰腺癌、卵巢癌、睾丸癌、乳腺癌、膀胱癌、胆囊癌、骨髓增生异常综合症、淋巴瘤、食管癌、胃肠道癌、星型细胞瘤、神经母细胞瘤、神经胶质瘤、神经鞘瘤、间皮瘤、非胰岛素依赖型糖尿病、自身免疫性疾病。
本发明通过将酰胺键CU环化形成五元环得到一类结构新型、高效的HDACs抑制剂。其有益效果是:对HDACs具有优良的抑制活性并且还具有优良的体外抗肿瘤活性,为HDAC抑制剂在实体瘤中的应用提供新的研究途径。
实施方式
实施例
(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基丁酰胺(Ⅰ-1)
,
步骤a:(E)-3-亚苄基吡咯烷-2,5-二酮的合成
按顺序在100 mL圆底烧瓶中加入马来酰亚胺(5 mmol,485.35 mg)、甲醇(10 mL)、三苯基膦(6 mmol,1.57 g)、苯甲醛(7.5 mmol, 795 mg),60℃回流搅拌反应8h。冷却至室温,有固体析出,抽滤烘干滤饼,得到白色固体750mg,收率80.1%。1H NMR (400 MHz, DMSO-d6) δ 11.45 (s, 1H), 7.66 – 7.59 (m, 2H), 7.52 – 7.41 (m, 3H), 7.39 (t, J =2.5 Hz, 1H), 3.66 (d, J = 2.5 Hz, 2H)。
步骤b:(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)丁酸乙酯的合成
按顺序在100 mL圆底烧瓶中加入(E)-3-亚苄基吡咯烷-2,5-二酮(749mg,4mmol)、DMF(10 mL)、碳酸钾(829mg,6 mmol),冰浴搅拌30min,移除冰浴待反应回到常温加入溴丁酸乙酯(1.56 g,8mmol),常温搅拌8 h。用水以及乙酸乙酯萃取,取有机层浓缩,经以石油醚:乙酸乙酯体积比为3: 1的混合溶剂作为洗脱剂柱层析洗脱,分离得到透明液体678mg,收率56.2%。1H NMR (300 MHz, Chloroform-d) δ 7.71 – 7.36 (m, 6H), 4.13(q, J = 7.1 Hz, 2H), 3.70 (t, J = 6.9 Hz, 2H), 3.57 (d, J = 2.4 Hz, 2H), 2.36(t, J = 7.4 Hz, 2H), 1.99 (p, J = 7.2 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H)。
步骤c:(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基丁酰胺的合成
在50 mL圆底烧瓶中加入(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)丁酸乙酯(600mg,1.99mmol)、冰醋酸3mL、浓盐酸0.5mL,90℃搅拌反应,TLC监控反应完全完成,将反应液冷却加入水中,有固体析出,过滤、收集并干燥滤饼。
取50mL圆底烧瓶,加入已干燥的滤饼,用四氢呋喃5mL溶解,加入N,N-碳基二咪唑484mg搅拌反应,1小时后,缓慢加入盐酸羟胺(415mg,5.97mmol),搅拌反应12h,将反应液浓缩,经以二氯甲烷:甲醇体积比为25: 1的混合溶剂作为洗脱剂柱层析洗脱,分离得到微黄色固体63mg,收率为11%。1H NMR (400 MHz, DMSO-d6) δ 10.36 (s, 1H), 8.71 (s, 1H),7.69 – 7.62 (m, 2H), 7.48 (qt, J = 6.9, 3.7 Hz, 5H), 3.70 (d, J = 2.4 Hz,2H), 3.50 (t, J = 7.1 Hz, 2H), 2.03 – 1.94 (m, 2H), 1.76 (p, J = 7.5 Hz, 2H).13C NMR (101 MHz, DMSO-d6) δ 174.78, 171.15, 168.83, 134.60, 132.37, 130.70,130.27, 129.46, 125.80, 38.29, 34.20, 30.28, 24.05.
实施例
(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基戊酰胺(Ⅰ-2)
,
步骤a:(E)-3-亚苄基吡咯烷-2,5-二酮的合成
操作与投料与实施例1步骤a相同。
步骤b:(E)-5-(3-亚苄基-2,5-二氧代吡咯烷基)戊酸乙酯的合成
以溴戊酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-5-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基戊酰胺的合成,
以(E)-5-(3-亚苄基-2,5-二氧代吡咯烷基)戊酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率15.2%。1H NMR (400 MHz, DMSO-d6) δ 10.36(s, 1H), 8.71 (s, 1H), 7.69 – 7.61 (m, 2H), 7.53 – 7.40 (m, 4H), 3.72 (d, J =2.4 Hz, 2H), 3.48 (t, J = 6.2 Hz, 2H), 1.97 (t, J = 6.6 Hz, 2H), 1.58 – 1.48(m, 2H), 1.51 – 1.41 (m, 2H).
13C NMR (101 MHz, DMSO) δ 174.80, 171.16, 169.23, 134.59, 132.42,130.71, 130.28, 129.45, 125.74, 38.29, 34.15, 32.28, 27.44, 23.00.
实施例
(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基己酰胺(Ⅰ-3)
,
步骤a:(E)-3-亚苄基吡咯烷-2,5-二酮的合成
操作与投料与实施例1步骤a相同。
步骤b:(E)-6-(3-亚苄基-2,5-二氧代吡咯烷基)己酸乙酯的合成
以溴己酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-6-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基己酰胺的合成,
以(E)-6-(3-亚苄基-2,5-二氧代吡咯烷基)己酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。黄色固体,收率18.2%。1H NMR (400 MHz, DMSO-d6) δ 10.33(s, 1H), 8.66 (s, 1H), 7.69 – 7.62 (m, 2H), 7.56 – 7.40 (m, 4H), 3.72 (d, J =2.4 Hz, 2H), 3.48 (t, J = 7.2 Hz, 2H), 1.94 (t, J = 7.4 Hz, 2H), 1.52 (dqd, J= 15.6, 7.7, 0.0 Hz, 4H), 1.31 – 1.17 (m, 2H).
13C NMR (101 MHz, DMSO) δ 174.79, 171.15, 169.45, 134.58, 132.40,130.70, 130.28, 129.45, 125.74, 38.43, 34.14, 32.52, 27.57, 26.33, 25.18.
实施例
(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基庚酰胺(Ⅰ-4)
步骤a:(E)-3-亚苄基吡咯烷-2,5-二酮的合成
操作与投料与实施例1步骤a相同。
步骤b:(E)-7-(3-亚苄基-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成,
以((E)-7-(3-亚苄基-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率16.1%。1H NMR (400 MHz, DMSO-d6) δ10.34 (s, 1H), 8.66 (s, 1H), 7.68 – 7.62 (m, 2H), 7.47 (qt, J = 6.9, 3.6 Hz,4H), 3.71 (d, J = 2.4 Hz, 2H), 3.48 (t, J = 7.2 Hz, 2H), 1.94 (t, J = 7.4 Hz,2H), 1.58 – 1.42 (m, 4H), 1.32 – 1.21 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.78, 171.15, 169.53, 134.60, 132.38,130.70, 130.26, 129.44, 125.76, 38.48, 34.14, 32.64, 28.63, 27.67, 26.44,25.45.
实施例
(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基辛酰胺(Ⅰ-5)
步骤a:(E)-3-亚苄基吡咯烷-2,5-二酮的合成
操作与投料与实施例1步骤a相同。
步骤b:(E)-8-(3-亚苄基-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴辛酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-8-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成,
以(E)-8-(3-亚苄基-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。淡黄色固体,收率20.2%。1H NMR (400 MHz, DMSO-d6) δ10.33 (s, 1H), 8.66 (s, 1H), 7.71 – 7.61 (m, 2H), 7.53 – 7.40 (m, 4H), 3.72(d, J = 2.4 Hz, 2H), 3.48 (t, J = 7.2 Hz, 2H), 1.93 (t, J = 7.3 Hz, 2H), 1.56– 1.43 (m, 4H), 1.31 – 1.19 (m, 6H).
13C NMR (101 MHz, DMSO) δ 174.76, 171.15, 169.60, 134.58, 132.40,130.68, 130.25, 129.43, 125.72, 38.50, 34.13, 32.71, 28.94, 28.78, 27.75,26.65, 25.53.
实施例
(E)-N-(2-氨基-4-氟苯基)-4-(3-亚苄基-2,5-二酮吡咯烷基)丁酰胺(Ⅰ-6)
步骤a:(E)-3-亚苄基吡咯烷-2,5-二酮的合成
操作与投料与实施例1步骤a相同。
步骤b:(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)丁酸乙酯的合成
以溴丁酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-N-(2-氨基-4-氟苯基)-4-(3-亚苄基-2,5-二酮吡咯烷基)丁酰胺的合成,
以(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)丁酸乙酯与4-氟邻苯二胺为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率25.2%。1H NMR (400 MHz,DMSO-d6) δ 9.01 (s, 1H), 7.69 – 7.62 (m, 2H), 7.52 – 7.42 (m, 4H), 7.11 –7.01 (m, 1H), 6.48 (dd, J = 11.2, 2.9 Hz, 1H), 6.27 (td, J = 8.6, 2.9 Hz,1H), 5.18 (s, 2H), 3.71 (d, J = 2.4 Hz, 2H), 3.57 (t, J = 6.9 Hz, 2H), 2.34(t, J = 7.5 Hz, 2H), 1.88 (p, J = 7.1 Hz, 2H).
13C NMR (101 MHz, DMSO) δ 174.88, 171.25, 171.11, 162.25, 159.88,145.06, 144.94, 134.58, 132.44, 130.70, 130.29, 129.47, 127.92, 127.82,125.77, 119.76, 102.35, 102.13, 101.75, 101.50, 38.20, 34.22, 33.27, 23.78.
实施例
(E)-N-(2-氨基-4-氟苯基)-5-(3-亚苄基-2,5-二酮吡咯烷基)戊酰胺(Ⅰ-7)
步骤a:(E)-3-亚苄基吡咯烷-2,5-二酮的合成
操作与投料与实施例1步骤a相同。
步骤b:(E)-5-(3-亚苄基-2,5-二氧代吡咯烷基)戊酸乙酯的合成
以溴戊酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-N-(2-氨基-4-氟苯基)-4-(3-亚苄基-2,5-二酮吡咯烷基)丁酰胺的合成,
以((E)-5-(3-亚苄基-2,5-二氧代吡咯烷基)戊酸乙酯与4-氟邻苯二胺为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率36.8%。1H NMR (300 MHz,DMSO-d6) δ 9.03 (s, 1H), 7.72 – 7.59 (m, 2H), 7.55 – 7.37 (m, 4H), 7.09 (dd,J = 8.7, 6.3 Hz, 1H), 6.48 (dd, J = 11.2, 2.9 Hz, 1H), 6.30 (td, J = 8.5, 2.9Hz, 1H), 5.15 (s, 2H), 3.73 (d, J = 2.3 Hz, 2H), 3.53 (t, J = 5.5 Hz, 2H),2.33 (t, J = 6.9 Hz, 2H), 1.65 – 1.50 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.82, 171.53, 171.19, 162.13, 159.77,144.78, 144.66, 134.59, 132.42, 130.70, 130.28, 129.45, 127.62, 127.52,125.77, 119.95, 119.92, 102.43, 102.21, 101.89, 101.64, 38.37, 35.55, 34.17,27.42, 22.97.
实施例
(E)-N-(2-氨基-4-氟苯基)-6-(3-亚苄基-2,5-二酮吡咯烷基)己酰胺(Ⅰ-8)
步骤a:(E)-3-亚苄基吡咯烷-2,5-二酮的合成
操作与投料与实施例1步骤a相同。
步骤b:(E)-6-(3-亚苄基-2,5-二氧代吡咯烷基)己酸乙酯的合成
以溴己酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-N-(2-氨基-4-氟苯基)-6-(3-亚苄基-2,5-二酮吡咯烷基)己酰胺的合成,
以((E)-6-(3-亚苄基-2,5-二氧代吡咯烷基)己酸乙酯与4-氟邻苯二胺为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率36.8%。1H NMR (300 MHz,DMSO-d6) δ 9.03 (s, 1H), 7.72 – 7.59 (m, 2H), 7.55 – 7.37 (m, 4H), 7.09 (dd,J = 8.7, 6.3 Hz, 1H), 6.48 (dd, J = 11.2, 2.9 Hz, 1H), 6.30 (td, J = 8.5, 2.9Hz, 1H), 5.15 (s, 2H), 3.73 (d, J = 2.3 Hz, 2H), 3.53 (t, J = 5.5 Hz, 2H),2.33 (t, J = 6.9 Hz, 2H), 1.65 – 1.50 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.82, 171.53, 171.19, 162.13, 159.77,144.78, 144.66, 134.59, 132.42, 130.70, 130.28, 129.45, 127.62, 127.52,125.77, 119.95, 119.92, 102.43, 102.21, 101.89, 101.64, 38.37, 35.55, 34.17,27.42, 22.97.
实施例
(E)-N-(2-氨基-4-氟苯基)-7-(3-亚苄基-2,5-二酮吡咯烷基)庚酰胺(Ⅰ-9)
步骤a:(E)-3-亚苄基吡咯烷-2,5-二酮的合成
操作与投料与实施例1步骤a相同。
步骤b:(E)-7-(3-亚苄基-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-N-(2-氨基-4-氟苯基)-7-(3-亚苄基-2,5-二酮吡咯烷基)庚酰胺的合成,
以(E)-7-(3-亚苄基-2,5-二氧代吡咯烷基)庚酸乙酯与4-氟邻苯二胺为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率32.9%。1H NMR (300 MHz,DMSO-d6) δ 9.02 (s, 1H), 7.73 – 7.59 (m, 2H), 7.53 – 7.37 (m, 4H), 7.09 (dd,J = 8.7, 6.3 Hz, 1H), 6.48 (dd, J = 11.2, 2.9 Hz, 1H), 6.29 (td, J = 8.6, 2.9Hz, 1H), 5.13 (s, 2H), 3.72 (d, J = 2.4 Hz, 2H), 3.50 (t, J = 7.1 Hz, 2H),2.29 (t, J = 7.4 Hz, 2H), 1.67 – 1.47 (m, 4H), 1.40 – 1.23 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.81, 171.82, 171.18, 162.39, 159.61,144.77, 144.65, 134.60, 132.38, 130.70, 130.27, 129.45, 127.59, 127.49,125.77, 120.04, 102.47, 102.24, 101.93, 101.68, 38.49, 36.03, 34.15, 28.75,27.69, 26.52, 25.56.
实施例
4-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)丁酰胺(Ⅰ-10)
步骤a:(E)-3-亚苄基吡咯烷-2,5-二酮的合成
操作与投料与实施例1步骤a相同。
步骤b:(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)丁酸乙酯的合成
以溴丁酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:4-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)丁酰胺的合成,
以(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)丁酸乙酯与(1S,2S)-2-氨基环己醇为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率35.8%。1H NMR (400MHz, DMSO-d6) δ 7.68 – 7.63 (m, 2H), 7.59 (d, J = 8.0 Hz, 1H), 7.52 – 7.42(m, 4H), 4.50 (d, J = 4.8 Hz, 1H), 3.70 (d, J = 2.4 Hz, 2H), 3.51 (t, J = 7.1Hz, 3H), 3.41 (m, 1H), 3.20 (m, 1H), 2.10 (t, J = 7.0 Hz, 2H), 1.76 (p, J =7.5 Hz, 2H), 1.64 – 1.51 (m, 2H), 1.31 – 0.99 (m, 6H).
13C NMR (101 MHz, DMSO) δ 174.80, 171.57, 171.18, 134.60, 132.38,130.69, 130.27, 129.47, 125.79, 71.73, 54.58, 38.32, 34.40, 34.20, 33.46,31.42, 24.54, 24.19, 24.13.
实施例
5-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)戊酰胺(Ⅰ-11)
步骤a:(E)-3-亚苄基吡咯烷-2,5-二酮的合成
操作与投料与实施例1步骤a相同。
步骤b:(E)-5-(3-亚苄基-2,5-二氧代吡咯烷基)戊酸乙酯的合成
以溴戊酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:5-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)戊酰胺的合成,
以(E)-5-(3-亚苄基-2,5-二氧代吡咯烷基)戊酸乙酯与(1S,2S)-2-氨基环己醇为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率40.6%。1H NMR (400MHz, DMSO-d6) δ 7.69 – 7.63 (m, 2H), 7.57 (d, J = 7.8 Hz, 1H), 7.51 – 7.42(m, 4H), 4.50 (d, J = 4.9 Hz, 1H), 3.72 (d, J = 2.5 Hz, 2H), 3.49 (t, J = 6.5Hz, 2H), 3.42 – 3.36 (m, 1H), 3.20 (m, 1H), 2.09 (t, J = 6.6 Hz, 2H), 1.87 –1.72 (m, 2H), 1.62 – 1.43 (m, 6H), 1.24 – 1.06 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.78, 172.09, 171.15, 134.59, 132.41,130.70, 130.27, 129.45, 125.76, 71.74, 54.54, 38.39, 35.50, 34.47, 34.15,31.46, 27.43, 24.53, 24.20, 23.16.
实施例
6-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)己酰胺(Ⅰ-12)
/>
步骤a:(E)-3-亚苄基吡咯烷-2,5-二酮的合成
操作与投料与实施例1步骤a相同。
步骤b:(E)-6-(3-亚苄基-2,5-二氧代吡咯烷基)己酸乙酯的合成
以溴己酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:6-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)己酰胺的合成,
以(E)-6-(3-亚苄基-2,5-二氧代吡咯烷基)己酸乙酯与(1S,2S)-2-氨基环己醇为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率38.5%。1H NMR (400MHz, DMSO-d6) δ 7.71 – 7.61 (m, 2H), 7.54 (d, J = 7.8 Hz, 1H), 7.52 – 7.41(m, 4H), 4.48 (d, J = 5.1 Hz, 1H), 3.71 (d, J = 2.4 Hz, 2H), 3.48 (t, J = 7.1Hz, 2H), 3.42 – 3.35 (m, 1H), 3.24 – 3.15 (m, 1H), 2.06 (t, J = 7.4 Hz, 2H),1.86 – 1.70 (m, 2H), 1.64 – 1.45 (m, 6H), 1.30 – 1.00 (m, 6H).
13C NMR (101 MHz, DMSO) δ 174.75, 172.34, 171.13, 134.59, 132.39,130.69, 130.26, 129.44, 125.74, 71.81, 54.55, 38.47, 35.81, 34.51, 34.14,31.46, 27.61, 26.35, 25.41, 24.54, 24.21.
实施例
7-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)庚酰胺(Ⅰ-13)
步骤a:(E)-3-亚苄基吡咯烷-2,5-二酮的合成
操作与投料与实施例1步骤a相同。
步骤b:(E)-7-(3-亚苄基-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:7-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)庚酰胺的合成,
以(E)-7-(3-亚苄基-2,5-二氧代吡咯烷基)庚酸乙酯与(1S,2S)-2-氨基环己醇为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率48.1%。1H NMR (400MHz, DMSO-d6) δ 7.69 – 7.62 (m, 2H), 7.54 (d, J = 7.8 Hz, 1H), 7.51 – 7.42(m, 4H), 4.48 (d, J = 5.0 Hz, 1H), 3.72 (d, J = 2.4 Hz, 2H), 3.48 (t, J = 7.2Hz, 2H), 3.42 – 3.35 (m, 1H), 3.25 – 3.15 (m, 1H), 2.05 (t, J = 7.4 Hz, 2H),1.87 – 1.70 (m, 2H), 1.64 – 1.40 (m, 6H), 1.29 – 1.22 (m, 4H), 1.22 – 1.07(m, 4H).
13C NMR (101 MHz, DMSO) δ 174.79, 172.43, 171.16, 134.60, 132.37,130.70, 130.26, 129.45, 125.78, 71.78, 54.53, 38.51, 35.94, 34.52, 34.14,31.47, 28.70, 27.70, 26.53, 25.68, 24.54, 24.20.
实施例
8-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)辛酰胺(Ⅰ-14)
步骤a:(E)-3-亚苄基吡咯烷-2,5-二酮的合成
操作与投料与实施例1步骤a相同。
步骤b:(E)-8-(3-亚苄基-2,5-二氧代吡咯烷基)辛酸乙酯的合成
以溴辛酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:8-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)辛酰胺的合成,
以(E)-8-(3-亚苄基-2,5-二氧代吡咯烷基)辛酸乙酯与(1S,2S)-2-氨基环己醇为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率36.2%。1H NMR (400MHz, DMSO-d6) δ 7.69 – 7.61 (m, 2H), 7.54 (d, J = 7.8 Hz, 1H), 7.51 – 7.43(m, 4H), 4.49 (d, J = 5.0 Hz, 1H), 3.72 (d, J = 2.4 Hz, 2H), 3.48 (t, J = 7.2Hz, 2H), 3.42 – 3.35 (m, 1H), 3.24 – 3.15 (m, 1H), 2.05 (t, J = 7.4 Hz, 2H),1.87 – 1.71 (m, 2H), 1.61 – 1.42 (m, 6H), 1.31 – 1.09 (m, 10H).
13C NMR (101 MHz, DMSO) δ 174.77, 172.49, 171.15, 134.61, 132.38,130.69, 130.25, 129.44, 125.77, 71.79, 54.54, 38.51, 36.02, 34.50, 34.14,31.46, 28.97, 28.84, 27.75, 26.66, 25.75, 24.54, 24.20.
实施例
(E)-7-(3-(4-异丙基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-15)
步骤a:(E)-3-(4-异丙基亚苄基)吡咯烷-2,5-二酮的合成
以4-异丙基苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(4-异丙基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(4-异丙基亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(4-异丙基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率26.6%。1H NMR (400 MHz, DMSO-d6) δ 10.33 (s, 1H), 8.65 (s, 1H), 7.57 (d, J = 8.1 Hz, 2H), 7.44 (t, J = 2.2Hz, 1H), 7.36 (d, J = 8.2 Hz, 2H), 3.70 (d, J = 2.4 Hz, 2H), 3.47 (t, J = 7.2Hz, 2H), 2.94 (hept, J = 6.8 Hz, 1H), 1.93 (t, J = 7.3 Hz, 2H), 1.56 – 1.42(m, 4H), 1.28 – 1.20 (m, 10H).
13C NMR (101 MHz, DMSO) δ 174.84, 171.25, 169.51, 150.98, 132.40,132.29, 130.87, 127.44, 124.69, 38.46, 34.14, 33.82, 32.64, 28.63, 27.68,26.45, 25.45, 24.08.
实施例
(E)-7-(3-(4-二甲氨基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-16)
步骤a:(E)-3-(4-二甲氨基亚苄基)吡咯烷-2,5-二酮的合成
以4-二甲氨基苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(4-二甲氨基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(4-二甲氨基亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(4-二甲氨基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。黄色固体,收率32.1%。1H NMR (300 MHz,DMSO-d6) δ 10.35 (s, 1H), 8.68 (s, 1H), 7.46 (d, J = 8.5 Hz, 2H), 7.35 (t, J= 2.0 Hz, 1H), 6.76 (d, J = 8.4 Hz, 2H), 3.61 (d, J = 2.2 Hz, 2H), 3.45 (t, J= 7.1 Hz, 2H), 2.99 (s, 6H), 1.93 (t, J = 7.3 Hz, 2H), 1.57 – 1.41 (m, 4H),1.30 – 1.15 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.98, 171.51, 169.53, 151.56, 133.35,132.48, 121.95, 119.01, 112.34, 40.10, 38.29, 34.25, 32.65, 28.64, 27.77,26.46, 25.46.
实施例
(E)-7-(3-(4-三氟甲基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-17)
/>
步骤a:(E)-3-(4-三氟甲基亚苄基)吡咯烷-2,5-二酮的合成
以4-三氟甲基苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(4-三氟甲基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(4-三氟甲基亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(4-三氟甲基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率15.8%。1H NMR (400 MHz,DMSO-d6) δ 10.33 (s, 1H), 8.65 (s, 1H), 7.88 (d, J = 8.3 Hz, 2H), 7.82 (d, J= 8.3 Hz, 2H), 7.55 (t, J = 2.3 Hz, 1H), 3.77 (d, J = 2.4 Hz, 2H), 3.49 (t, J= 7.2 Hz, 2H), 1.93 (t, J = 7.4 Hz, 2H), 1.59 – 1.43 (m, 4H), 1.29 – 1.22 (m,4H).
13C NMR (101 MHz, DMSO) δ 174.60, 170.84, 169.51, 138.61, 131.19,130.53, 129.91, 129.59, 128.77, 126.16, 126.12, 125.83, 123.12, 38.58, 34.13,32.63, 28.62, 27.62, 26.43, 25.44.
实施例
(E)-7-(3-(4-甲基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-18)
步骤a:(E)-3-(4-甲基亚苄基)吡咯烷-2,5-二酮的合成
以4-甲基苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(4-甲基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(4-甲基亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(4-甲基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率26.7%。1H NMR (400 MHz, DMSO-d6)δ 10.33 (s, 1H), 8.65 (s, 1H), 7.54 (d, J = 5.8 Hz, 2H), 7.47 – 7.40 (m, 1H),7.30 (d, J = 5.8 Hz, 2H), 3.69 (d, J = 2.9 Hz, 2H), 3.48 (t, J = 6.0 Hz, 2H),2.36 (s, 3H), 1.94 (t, J = 6.9 Hz, 2H), 1.56 – 1.41 (m, 4H), 1.30 – 1.19 (m,4H).
13C NMR (101 MHz, DMSO) δ 174.82, 171.24, 169.52, 140.28, 132.42,131.88, 130.73, 130.08, 124.62, 38.44, 34.16, 32.64, 28.62, 27.68, 26.43,25.44, 21.48.
实施例
(E)-7-(3-(2-甲基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-19)
步骤a:(E)-3-(2-甲基亚苄基)吡咯烷-2,5-二酮的合成
以2-甲基苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(2-甲基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(2-甲基亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(2-甲基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率35.2%。1H NMR (400 MHz, DMSO-d6)δ 10.35 (s, 1H), 8.68 (s, 1H), 7.64 (t, J = 2.4 Hz, 1H), 7.56 (d, J = 7.1 Hz,1H), 7.36 – 7.25 (m, 3H), 3.65 (d, J = 2.4 Hz, 2H), 3.48 (t, J = 7.2 Hz, 2H),2.39 (s, 3H), 1.93 (t, J = 7.4 Hz, 2H), 1.58 – 1.44 (m, 4H), 1.29 – 1.20 (m,4H).
13C NMR (101 MHz, DMSO) δ 174.88, 171.07, 169.57, 138.63, 133.24,131.10, 130.06, 129.81, 128.65, 126.81, 126.45, 38.47, 33.77, 32.64, 28.61,27.66, 26.44, 25.43, 19.94.
实施例
(E)-7-(3-(2-氰基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-20)
步骤a:(E)-3-(2-氰基亚苄基)吡咯烷-2,5-二酮的合成
以2-氰基苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(2-氰基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(2-氰基亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(2-氰基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率12.1%。1H NMR (400 MHz, DMSO-d6)δ 10.33 (s, 1H), 8.65 (s, 1H), 7.99 (dd, J = 7.8, 1.4 Hz, 1H), 7.90 (d, J =7.9 Hz, 1H), 7.82 (td, J = 7.8, 1.4 Hz, 1H), 7.67 – 7.61 (m, 2H), 3.77 (d, J= 2.5 Hz, 2H), 3.50 (t, J = 7.1 Hz, 2H), 1.94 (t, J = 7.4 Hz, 2H), 1.60 –1.44 (m, 4H), 1.30 – 1.22 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.43, 170.56, 169.53, 136.91, 134.17,134.16, 130.86, 130.59, 129.42, 126.63, 117.72, 113.25, 38.70, 34.04, 32.65,28.62, 27.59, 26.44, 25.44.
实施例
(E)-7-(3-(2-亚甲基吡啶)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-21)
步骤a:(E)-3-(2-亚甲基吡啶)吡咯烷-2,5-二酮的合成
以2-吡啶甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(2-亚甲基吡啶)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(2-亚甲基吡啶)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(2-亚甲基吡啶)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。黄色固体,收率16.8%。1H NMR (300 MHz, DMSO-d6)δ 10.35 (s, 1H), 8.73 (d, J = 4.5 Hz, 1H), 8.68 (s, 1H), 7.90 (td, J = 7.7,1.8 Hz, 1H), 7.76 (d, J = 7.7 Hz, 1H), 7.48 (t, J = 2.2 Hz, 1H), 7.40 (ddd, J= 7.5, 4.7, 1.3 Hz, 1H), 3.78 (d, J = 2.3 Hz, 2H), 3.48 (t, J = 7.2 Hz, 2H),1.93 (t, J = 7.3 Hz, 2H), 1.59 – 1.42 (m, 4H), 1.32 – 1.19 (m, 4H).
13C NMR (101 MHz, DMSO) δ 175.36, 171.10, 169.66, 153.68, 150.53,137.58, 130.42, 129.55, 127.54, 124.19, 38.45, 35.37, 32.61, 28.58, 27.62,26.40, 25.41.
实施例
(E)-7-(3-(2-亚甲基萘基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-22)
步骤a:(E)-3-(2-亚甲基萘基)吡咯烷-2,5-二酮的合成
以2-萘甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(2-亚甲基萘基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(2-亚甲基萘基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(2-亚甲基萘基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率18.2%。1H NMR (400 MHz, DMSO-d6)δ 10.33 (s, 1H), 8.66 (s, 1H), 8.25 (s, 1H), 8.07 – 7.92 (m, 3H), 7.77 (dd, J= 8.6, 1.8 Hz, 1H), 7.63 (t, J = 2.4 Hz, 1H), 7.61 – 7.55 (m, 2H), 3.85 (d, J= 2.3 Hz, 2H), 3.50 (t, J = 7.2 Hz, 2H), 1.94 (t, J = 7.4 Hz, 2H), 1.50 (m,4H), 1.27 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.88, 171.20, 169.56, 133.59, 133.33,132.41, 132.20, 131.18, 129.11, 128.94, 128.05, 127.97, 127.23, 127.18,126.05, 38.52, 34.29, 32.64, 28.62, 27.67, 26.45, 25.45.
实施例
(E)-7-(3-(2-亚甲基噻吩基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-23)
步骤a:(E)-3-(2-亚甲基噻吩基)吡咯烷-2,5-二酮的合成
以2-噻吩甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(2-亚甲基噻吩基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(2-亚甲基噻吩基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(2-亚甲基噻吩基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。黄色固体,收率18.6%。1H NMR (400 MHz, DMSO-d6) δ 10.36 (s, 1H), 8.69 (s, 1H), 7.90 (d, J = 5.0 Hz, 1H), 7.72 (t, J = 2.4Hz, 1H), 7.60 (d, J = 3.7 Hz, 1H), 7.24 (t, J = 4.3 Hz, 1H), 3.52 (d, J = 2.3Hz, 2H), 3.46 (t, J = 7.2 Hz, 2H), 1.93 (t, J = 7.3 Hz, 2H), 1.58 – 1.42 (m,4H), 1.29 – 1.18 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.23, 170.77, 169.55, 138.65, 133.73,132.12, 128.88, 125.49, 122.97, 38.52, 34.12, 32.63, 28.62, 27.69, 26.42,25.45.
实施例24
(E)-7-(3-(2-氯亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-24)
步骤a:(E)-3-(2-氯亚苄基)吡咯烷-2,5-二酮的合成
以2-氯苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(2-氯亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(2-氯亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(2-氯亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。淡黄色固体,收率10.2%。1H NMR (300 MHz, DMSO-d6)δ 10.34 (s, 1H), 8.67 (s, 1H), 7.80 – 7.73 (m, 1H), 7.71 (t, J = 2.2 Hz, 1H),7.64 – 7.57 (m, 1H), 7.50 – 7.41 (m, 2H), 3.71 (d, J = 2.4 Hz, 2H), 3.49 (t,J = 7.1 Hz, 2H), 1.94 (t, J = 7.3 Hz, 2H), 1.60 – 1.40 (m, 4H), 1.31 – 1.18(m, 4H).
13C NMR (101 MHz, DMSO) δ 174.63, 170.79, 169.55, 134.82, 132.19,131.72, 130.45, 130.42, 128.77, 128.23, 127.33, 38.59, 33.68, 32.64, 28.61,27.61, 26.43, 25.43.
实施例25
(E)-7-(3-(3-氯亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-25)
步骤a:(E)-3-(3-氯亚苄基)吡咯烷-2,5-二酮的合成
以3-氯苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(3-氯亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(3-氯亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(3-氯亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。淡黄色固体,收率12.6%。1H NMR (400 MHz, DMSO-d6)δ 10.33 (s, 1H), 8.65 (s, 1H), 7.72 (s, 1H), 7.65 – 7.60 (m, 1H), 7.50 (d, J= 4.5 Hz, 2H), 7.47 (t, J = 2.4 Hz, 1H), 3.75 (d, J = 2.4 Hz, 2H), 3.48 (t, J= 7.2 Hz, 2H), 1.93 (t, J = 7.3 Hz, 2H), 1.57 – 1.42 (m, 4H), 1.30 – 1.21 (m,4H).
13C NMR (101 MHz, DMSO) δ 174.67, 170.93, 169.59, 136.74, 134.14,131.23, 130.83, 130.18, 129.93, 128.97, 127.49, 38.54, 34.00, 32.62, 28.59,27.61, 26.41, 25.43.
实施例26
(E)-7-(3-(4-氯亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-26)
步骤a:(E)-3-(4-氯亚苄基)吡咯烷-2,5-二酮的合成
以4-氯苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(4-氯亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(4-氯亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(4-氯亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。黄色固体,收率15.8%。1H NMR (400 MHz, DMSO-d6) δ10.33 (s, 1H), 8.65 (s, 1H), 7.68 (d, J = 8.7 Hz, 2H), 7.54 (d, J = 8.5 Hz,2H), 7.47 (t, J = 2.4 Hz, 1H), 3.71 (d, J = 2.4 Hz, 2H), 3.48 (t, J = 7.2 Hz,2H), 1.93 (t, J = 7.4 Hz, 2H), 1.59 – 1.42 (m, 4H), 1.33 – 1.20 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.67, 171.01, 169.55, 134.86, 133.53,132.35, 131.01, 129.46, 126.59, 38.52, 34.07, 32.64, 28.61, 27.63, 26.42,25.43.
实施例27
(E)-7-(3-(3-溴亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-27)
步骤a:(E)-3-(3-溴亚苄基)吡咯烷-2,5-二酮的合成
以3-溴苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(3-溴亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(3-溴亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(3-溴亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率26.2%。1H NMR (400 MHz, DMSO-d6) δ10.35 (s, 1H), 8.68 (s, 1H), 7.85 (s, 1H), 7.70 – 7.60 (m, 2H), 7.46 (t, J =2.3 Hz, 1H), 7.43 (d, J = 7.8 Hz, 1H), 3.75 (d, J = 2.4 Hz, 2H), 3.48 (t, J =7.1 Hz, 2H), 1.93 (t, J = 7.3 Hz, 2H), 1.57 – 1.43 (m, 4H), 1.29 – 1.21 (m,4H).
13C NMR (101 MHz, DMSO) δ 174.67, 170.90, 169.52, 137.03, 133.11,132.82, 131.47, 130.75, 129.27, 127.49, 122.71, 38.53, 34.00, 32.63, 28.61,27.64, 26.43, 25.44.
实施例28
(E)-7-(3-(3-氟亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-28)
步骤a:(E)-3-(3-氟亚苄基)吡咯烷-2,5-二酮的合成
以3-氟苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(3-氟亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(3-氟亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(3-氟亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率29.6%。1H NMR (400 MHz, DMSO-d6) δ10.33 (s, 1H), 8.66 (s, 1H), 7.59 – 7.44 (m, 4H), 7.34 – 7.22 (m, 1H), 3.75(d, J = 2.4 Hz, 2H), 3.48 (t, J = 7.2 Hz, 2H), 1.93 (t, J = 7.4 Hz, 2H), 1.58– 1.42 (m, 4H), 1.32 – 1.18 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.69, 170.96, 169.52, 163.94, 161.51,136.99, 136.91, 131.42, 131.34, 131.03, 127.35, 126.85, 126.82, 117.13,117.06, 116.92, 116.84, 38.53, 34.02, 32.63, 28.62, 27.64, 26.43, 25.44.
实施例29
(E)-7-(3-(3-碘亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-29)
步骤a:(E)-3-(3-碘亚苄基)吡咯烷-2,5-二酮的合成
以3-碘苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(3-碘亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(3-碘亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(3-碘亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率18.6%。1H NMR (300 MHz, DMSO-d6) δ10.35 (s, 1H), 8.69 (s, 1H), 8.00 (s, 1H), 7.80 (d, J = 7.6 Hz, 1H), 7.67 (d,J = 7.8 Hz, 1H), 7.41 (t, J = 2.4 Hz, 1H), 7.27 (t, J = 7.8 Hz, 1H), 3.73 (d,J = 2.4 Hz, 2H), 3.47 (t, J = 7.1 Hz, 2H), 1.93 (t, J = 7.3 Hz, 2H), 1.57 –1.40 (m, 4H), 1.29 – 1.18 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.68, 170.91, 169.52, 138.95, 138.67,136.92, 131.41, 130.79, 129.55, 127.19, 95.92, 38.52, 33.98, 32.62, 28.61,27.64, 26.42, 25.44.
实施例30
(E)-7-(3-(3,4-二氯亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-30)
步骤a:(E)-3-(3,4-二氯亚苄基)吡咯烷-2,5-二酮的合成
以3,4-二氯苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(3,4-二氯亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(3,4-二氯亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(3,4-二氯亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。黄色固体,收率18.5%。1H NMR (400 MHz, DMSO-d6) δ 10.33 (s, 1H), 8.65 (s, 1H), 7.92 (s, 1H), 7.72 (d, J = 8.3 Hz, 1H),7.64 (d, J = 8.4 Hz, 1H), 7.46 (s, 1H), 3.75 (s, 2H), 3.48 (t, J = 7.1 Hz,2H), 1.93 (t, J = 7.3 Hz, 2H), 1.57 – 1.41 (m, 4H), 1.30 – 1.17 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.56, 170.78, 169.51, 135.38, 132.63,132.33, 132.19, 131.48, 130.26, 129.78, 128.08, 38.57, 33.94, 32.64, 28.62,27.62, 26.43, 25.44.
实施例31
(E)-7-(3-(2-甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-31)
步骤a:(E)-3-(2-甲氧基亚苄基)吡咯烷-2,5-二酮的合成
以2-甲氧基苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(2-甲氧基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(2-甲氧基亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(2-甲氧基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率19.3%。1H NMR (400 MHz, DMSO-d6) δ 10.33 (s, 1H), 8.65 (s, 1H), 7.77 (t, J = 2.4 Hz, 1H), 7.57 (dd, J =7.8, 1.6 Hz, 1H), 7.44 (ddd, J = 8.7, 7.3, 1.7 Hz, 1H), 7.12 (dd, J = 8.4,1.1 Hz, 1H), 7.07 – 7.01 (m, 1H), 3.88 (s, 3H), 3.66 (d, J = 2.4 Hz, 2H),3.47 (t, J = 7.1 Hz, 2H), 1.93 (t, J = 7.4 Hz, 2H), 1.56 – 1.42 (m, 4H), 1.29– 1.20 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.92, 171.26, 169.57, 158.48, 132.06,129.58, 126.54, 125.25, 122.92, 121.16, 111.99, 56.18, 38.43, 33.95, 32.63,28.61, 27.67, 26.43, 25.44.
实施例32
(E)-7-(3-(3-甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-32)
步骤a:(E)-3-(3-甲氧基亚苄基)吡咯烷-2,5-二酮的合成
以3-甲氧基苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(3-甲氧基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(3-甲氧基亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(3-甲氧基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率10.3%。1H NMR (400 MHz, DMSO-d6) δ 10.35 (s, 1H), 8.68 (s, 1H), 7.45 (s, 1H), 7.39 (t, J = 8.0 Hz, 1H),7.22 (d, J = 7.8 Hz, 1H), 7.19 (s, 1H), 7.02 (d, J = 8.2 Hz, 1H), 3.81 (s,3H), 3.74 (s, 2H), 3.48 (t, J = 7.2 Hz, 2H), 1.93 (t, J = 7.4 Hz, 2H), 1.61 –1.41 (m, 4H), 1.32 – 1.20 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.77, 171.12, 169.52, 159.94, 135.93,132.39, 130.49, 126.01, 122.96, 116.23, 115.69, 55.67, 38.48, 34.08, 32.64,28.62, 27.66, 26.43, 25.45.
实施例33
(E)-7-(3-(4-甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-33)
/>
步骤a:(E)-3-(4-甲氧基亚苄基)吡咯烷-2,5-二酮的合成
以4-甲氧基苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(4-甲氧基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(4-甲氧基亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(4-甲氧基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率12.5%。1H NMR (400 MHz, DMSO-d6) δ 10.34 (s, 1H), 8.67 (s, 1H), 7.61 (d, J = 9.1 Hz, 2H), 7.43 (t, J = 2.4Hz, 1H), 7.04 (d, J = 7.9 Hz, 2H), 3.82 (s, 3H), 3.66 (d, J = 2.1 Hz, 2H),3.46 (t, J = 7.2 Hz, 2H), 1.93 (t, J = 7.3 Hz, 2H), 1.53 – 1.43 (m, 4H), 1.26– 1.22 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.89, 171.35, 169.58, 160.98, 132.60,132.32, 127.21, 122.77, 114.97, 55.82, 38.40, 34.08, 32.63, 28.61, 27.69,26.43, 25.44.
实施例34
(E)-7-(3-(3,4-二甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-34)
步骤a:(E)-3-(3,4-二甲氧基亚苄基)吡咯烷-2,5-二酮的合成
以3,4-二甲氧基苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(3,4-二甲氧基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(3,4-二甲氧基亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(3,4-二甲氧基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率21.5%。1H NMR (400 MHz,DMSO-d6) δ 10.33 (s, 1H), 8.65 (s, 1H), 7.43 (t, J = 2.3 Hz, 1H), 7.23 (dd, J= 8.4, 2.1 Hz, 1H), 7.20 (d, J = 2.0 Hz, 1H), 7.05 (d, J = 8.4 Hz, 1H), 3.83(s, 3H), 3.82 (s, 3H), 3.73 (d, J = 2.3 Hz, 2H), 3.47 (t, J = 7.1 Hz, 2H),1.93 (t, J = 7.3 Hz, 2H), 1.54 – 1.43 (m, 4H), 1.28 – 1.22 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.92, 171.32, 169.52, 150.82, 149.22,132.76, 127.38, 124.63, 122.83, 113.58, 112.26, 56.06, 55.99, 38.41, 33.98,32.64, 28.63, 27.70, 26.44, 25.46.
实施例35
(E)-7-(3-(3,4,5-三甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-35)
步骤a:(E)-3-(3,4,5-三甲氧基亚苄基)吡咯烷-2,5-二酮的合成
以3,4,5-三甲氧基苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(3,4,5-三甲氧基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(3,4,5-三甲氧基亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(3,4,5-三甲氧基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率19.7%。1H NMR (400 MHz,DMSO-d6) δ 10.33 (s, 1H), 8.65 (s, 1H), 7.43 (t, J = 2.4 Hz, 1H), 6.95 (s,2H), 3.85 (s, 6H), 3.80 (d, J = 2.3 Hz, 2H), 3.71 (s, 3H), 3.48 (t, J = 7.1Hz, 2H), 1.93 (t, J = 7.4 Hz, 2H), 1.59 – 1.43 (m, 4H), 1.31 – 1.20 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.89, 171.18, 169.52, 153.46, 139.44,132.76, 130.11, 124.57, 108.23, 60.59, 56.46, 38.46, 33.85, 32.63, 28.62,27.67, 26.45, 25.46.
实施例36
(E)-7-(3-(4-羟基-3,5-二甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-36)
步骤a:(E)-3-(4-羟基-3,5-二甲氧基亚苄基)吡咯烷-2,5-二酮的合成
以4-羟基-3,5-二甲氧基苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(4-羟基-3,5-二甲氧基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(4-羟基-3,5-二甲氧基亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(4-羟基-3,5-二甲氧基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。黄色固体,收率13.1%。1H NMR (400MHz, DMSO-d6) δ 10.32 (s, 1H), 9.06 (s, 1H), 8.65 (s, 1H), 7.39 (s, 1H), 6.91(s, 2H), 3.82 (s, 6H), 3.75 (s, 2H), 3.48 (d, J = 7.2 Hz, 2H), 1.92 (t, J =7.3 Hz, 2H), 1.52 – 1.44 (m, 4H), 1.27 – 1.21 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.98, 171.35, 169.52, 148.46, 138.40,133.48, 124.91, 122.02, 108.63, 56.51, 38.38, 33.93, 32.64, 28.62, 27.71,26.45, 25.46.
实施例37
(E)-7-(3-(2-羟基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-37)
步骤a:(E)-3-(2-羟基亚苄基)吡咯烷-2,5-二酮的合成
以2-羟基苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(2-羟基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(2-羟基亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(2-羟基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率21.2%。1H NMR (400 MHz, DMSO-d6)δ 10.33 (s, 1H), 10.20 (s, 1H), 8.65 (s, 1H), 7.80 (t, J = 2.5 Hz, 1H), 7.49(d, J = 7.9 Hz, 1H), 7.25 (t, J = 7.6 Hz, 1H), 6.94 (d, J = 8.1 Hz, 1H), 6.88(t, J = 7.5 Hz, 1H), 3.65 (d, J = 2.7 Hz, 2H), 3.47 (t, J = 7.1 Hz, 2H), 1.93(t, J = 7.3 Hz, 2H), 1.62 – 1.42 (m, 4H), 1.34 – 1.18 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.94, 171.38, 169.54, 157.51, 131.82,129.56, 127.17, 123.88, 121.49, 119.87, 116.31, 38.41, 34.05, 32.64, 28.63,27.70, 26.45, 25.45.
实施例38
(E)-7-(3-(2-乙氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-38)
步骤a:(E)-3-(2-乙氧基亚苄基)吡咯烷-2,5-二酮的合成
以2-乙氧基苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(2-乙氧基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(2-乙氧基亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(2-乙氧基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率12.5%。1H NMR (300 MHz, DMSO-d6) δ 10.35 (s, 1H), 8.68 (s, 1H), 7.79 (t, J = 2.3 Hz, 1H), 7.57 (dd, J =7.8, 1.6 Hz, 1H), 7.41 (ddd, J = 8.8, 7.4, 1.6 Hz, 1H), 7.10 (dd, J = 8.4,1.0 Hz, 1H), 7.02 (t, J = 7.5 Hz, 1H), 4.13 (q, J = 6.9 Hz, 2H), 3.66 (d, J =2.4 Hz, 2H), 3.47 (t, J = 7.1 Hz, 2H), 1.93 (t, J = 7.3 Hz, 2H), 1.55 – 1.44(m, 4H), 1.38 (t, J = 6.9 Hz, 3H), 1.26 – 1.23 (m, 4H).
13C NMR (75 MHz, DMSO) δ 174.89, 171.25, 169.52, 157.82, 131.99,129.62, 126.64, 125.13, 123.03, 121.03, 112.81, 64.23, 38.43, 34.00, 32.63,28.63, 27.68, 26.44, 25.44, 15.07.
实施例39
(E)-7-(3-(5-溴-2-甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-39)
步骤a:(E)-3-(5-溴-2-甲氧基亚苄基)吡咯烷-2,5-二酮的合成
以5-溴-2-甲氧基苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(5-溴-2-甲氧基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(5-溴-2-甲氧基亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(5-溴-2-甲氧基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率19.8%。1H NMR (400 MHz,DMSO-d6) δ 10.33 (s, 1H), 8.65 (s, 1H), 7.65 (t, J = 2.4 Hz, 1H), 7.50 (d, J= 8.4 Hz, 1H), 7.33 (d, J = 1.9 Hz, 1H), 7.23 (dd, J = 8.3, 1.9 Hz, 1H), 3.90(s, 3H), 3.63 (d, J = 2.5 Hz, 2H), 3.46 (t, J = 7.2 Hz, 2H), 1.93 (t, J = 7.4Hz, 2H), 1.56 – 1.42 (m, 4H), 1.27 – 1.22 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.72, 171.06, 169.52, 159.07, 130.97,126.17, 125.42, 124.82, 124.10, 122.34, 115.37, 56.79, 38.48, 33.96, 32.64,28.62, 27.65, 26.43, 25.44.
实施例40
(E)-7-(3-(4-溴-2-甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-40)
步骤a:(E)-3-(4-溴-2-甲氧基亚苄基)吡咯烷-2,5-二酮的合成
以4-溴-2-甲氧基苯甲醛为原料,用类似实施例1中步骤a的方法合成目标化合物。
步骤b:(E)-7-(3-(4-溴-2-甲氧基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯的合成
以溴庚酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-7-(3-(4-溴-2-甲氧基亚苄基)-2,5-二氧代吡咯烷基)-N-羟基庚酰胺的合成
以((E)-7-(3-(4-溴-2-甲氧基亚苄基)-2,5-二氧代吡咯烷基)庚酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。白色固体,收率18.6%。1H NMR (400 MHz,DMSO-d6) δ 10.33 (s, 1H), 8.65 (s, 1H), 7.67 – 7.63 (m, 2H), 7.60 (dd, J =8.8, 2.4 Hz, 1H), 7.10 (d, J = 8.9 Hz, 1H), 3.88 (s, 3H), 3.70 (d, J = 2.5Hz, 2H), 3.47 (t, J = 7.2 Hz, 2H), 1.93 (t, J = 7.3 Hz, 2H), 1.56 – 1.42 (m,4H), 1.29 – 1.19 (m, 4H).
13C NMR (101 MHz, DMSO) δ 174.70, 170.92, 169.52, 157.63, 134.22,131.44, 127.04, 125.22, 125.12, 114.33, 112.73, 56.60, 38.50, 33.64, 32.64,28.61, 27.64, 26.42, 25.44.
实施例41
(E)-4-((3-亚苄基-2,5-二酮吡咯烷基)甲基)-N-羟基苯甲酰胺(Ⅰ-41)
步骤a:(E)-3-亚苄基吡咯烷-2,5-二酮的合成
操作与投料与实施例1步骤a相同。
步骤b:(E)-4-((3-亚苄基-2,5-二酮吡咯烷基)甲基)苯甲酸乙酯的合成
以4-溴甲基苯甲酸乙酯为原料,用类似实施例1中步骤b的方法合成目标化合物。
步骤c:(E)-4-((3-亚苄基-2,5-二酮吡咯烷基)甲基)-N-羟基苯甲酰胺的合成
以(E)-4-((3-亚苄基-2,5-二酮吡咯烷基)甲基)苯甲酸乙酯为原料,用类似实施例1中步骤c的方法合成目标化合物。黄色固体,收率11.3%。1H NMR (400 MHz, DMSO-d6) δ11.18 (s, 1H), 9.12 (s, 1H), 7.71 (d, J = 7.9 Hz, 2H), 7.67 (d, J = 7.0 Hz,2H), 7.54 – 7.43 (m, 4H), 7.36 (d, J = 7.9 Hz, 2H), 4.74 (s, 2H), 3.82 (d, J= 2.3 Hz, 2H).
13C NMR (101 MHz, DMSO) δ 174.67, 170.98, 164.41, 139.79, 134.50,132.98, 132.38, 130.77, 130.41, 129.49, 127.84, 127.56, 125.62, 41.69, 34.34.
对上述实施例所得化合物进行药理学试验,结果如下:
(1)目标化合物对HDAC抑制活性测定及结果
所合成的化合物用荧光共振能量转移(FRET)法测定对HDACl的抑制活性,并与阳性对照药比较,筛选出活性较好的化合物。HDACl通过纯化或直接购买试剂盒获得。
具体方法:
在反应孔中加入酶,对照孔中加入反应缓冲液,在反应孔中加入溶解在DMSO中的样品,使用非接触式纳升级声波移液***(Ech-550;纳升级)进行孵育。在每一个反应孔中加入荧光底物旋转震荡。30°C密封孵育1-2小时。加入含有TMP26的显色剂中止反应,产生荧光。使用EnVision多标记微孔板检测仪(Perkin Elmer)检测荧光强度(激发光: 490nm,发射光:520nm)。显色达到稳定后读取端点数值。使用GraphPad Prism 4软件进行 百分数(相对于DMSO对照组)抑制率的计算。
目标化合物对HDACl抑制活性结果:
/>
(2)目标化合物的体外抗肿瘤活性测定
使用MTT方法测定化合物对人非小细胞肺癌细胞株A549、NCI-H1650,人小细胞肺癌细胞株H446,人***癌细胞DU145、PC-3、LNCAP,人结肠癌细胞株HCT116,人乳腺癌细胞MDA-MB-231、MCF7肿瘤细胞株的抑制作用。
具体方法:收集处于指数生长期的细胞进行活细胞计数。用各细胞相应培养基调整细胞悬液浓度。每孔加100μL细胞悬液于96孔细胞培养板,置于37℃,5 %CO2箱中培养24小时。以DMSO溶解各供试化合物为相应浓度储存液。然后分别用培养基稀释至500倍溶液,各4复孔。每株细胞每孔分别加入100 μL相应的500倍溶液,DMSO终浓度为0. 1 %。药物处理96小时后,向各孔中加入10μL 5mg/mL MTT的PBS溶液, 置于37℃,5 %CO2箱中处理4h后,移去96孔板中的培养基,并往各孔中加入150mL DMSO,于酶标仪上检测吸光度。使用GraphPadPrism 4软件进行 半数(相对于DMSO对照组)抑制率的计算。
目标化合物对上述肿瘤细胞株的体外抗肿瘤活性(IC50)结果如下(单位:μM):
/>
以上药理测试结果表明,本发明通式I的化合物及其药学上可接受的盐对HDACs具有优良的抑制活性,因此,通式I化合物及其药学上可接受的盐可以用于治疗与上述靶标有关的临床病症。与HDACs有关的疾病可以是,但不限于:肺癌、黑色素瘤、肝癌、肾癌、白血病、非小细胞肺癌、***癌、甲状腺癌、皮肤癌、胰腺癌、卵巢癌、睾丸癌、乳腺癌、膀胱癌、胆囊癌、骨髓增生异常综合症、淋巴瘤、食管癌、甲状腺滤泡癌、胃肠道癌、中枢或外周神经***的肿瘤(例如星形细胞瘤、神经母细胞瘤、神经胶质瘤或神经鞘瘤)、间皮瘤、II型或非胰岛素依赖型糖尿病、自身免疫性疾病。
除上述实施外,本发明还可以有其他实施方式。凡采用等同替换或等效变换形成的技术方案,均落在本发明要求的保护范围。
Claims (7)
1. 通式 (Ⅰ)的化合物或其药学上可接受的盐,
,式中X、Y、Z、M1、M2各自独立地表示碳或者氮原子,且当选自氮原子时,仅一者为氮;
当X、Y、Z、M1、M2为碳原子时,各自独立地任选被R2取代,R2为氢、烷基、氰基、卤素、卤代烷基、羟基、巯基、烷氧基、烷氨基、烷硫基、烷氧基烷基、芳烷基、二芳基烷基、芳基或Het;
M3为碳,各自独立地任选被R4、R5取代,R4、R5为氢、氘、烷基、卤代烷基、羟基、巯基、烷氧基、烷氨基、烷硫基、烷氧基烷基、亚甲基、芳烷基、二芳基烷基、芳基或Het;
Q1是选自长度为1-8个碳原子的直链烷基、苯基;
R1为羟基、苯基或环己烷,
R3 是氢、烷基、氰基、卤素、卤代烷基、羟基、巯基、烷氧基、烷硫基、烷氧基烷基、芳烷基、芳基或Het;
烷基为具有1-7个碳原子的直链或支链饱和烃基;或为具有3-6个碳原子的环状饱和烃基;或为连接具有1-6个碳原子的直链或支链饱和烃基的具有3-6个碳原子的环状饱和烃基;
烷氧基为具有1-6个碳原子的直链或支链饱和烃基;或为具有3-6个碳原子的环状饱和烃基;或为连接具有1-6个碳原子的直链或支链饱和烃基的具有3-6个碳原子的环状饱和烃基;其中各碳原子任选被氧取代;
烷氨基为具有1-6个碳原子的直链或支链饱和烃基;或为具有3-6个碳原子的环状饱和烃基;或为连接具有1-6个碳原子的直链或支链饱和烃基的具有3-6个碳原子的环状饱和烃基;其中各碳原子任选被NH原子团取代;
烷氧基烷基如上定义的烷氧基与烷基连接;
烯基、炔基为具有1-6个碳原子的直链或支链的含有双键或三键的不饱和烃基;
芳基为选自苯基、萘基、苊基或四氢萘基的碳环,其各自任选被1、2或3个取代基取代,各取代基独立地选自氢、烷基、氰基、卤素、卤代烷基、羟基、巯基、烷氧基、烷硫基、烷氧基烷基、芳烷基、二芳基烷基、芳基或Het ;
芳烷基、二芳基烷基为如上定义的芳基与烷基连接;
Het为选自吡咯基、吡唑基、咪唑基、呋喃基、噻吩基、噁唑基、异噁唑基、噻唑基、异噻唑基、吡啶基、嘧啶基、吡嗪基或哒嗪基的单环杂环;或选自喹啉基、喹喔啉基、吲哚基、苯并咪唑基、苯并噁唑基、苯并异噁唑基、苯并噻唑基、苯并异噻唑基、苯并呋喃基、苯并噻吩基、2,3-二氢苯并[1,4]二氧杂环己烯基或苯并[1,3]二氧杂环戊烯基的双环杂环;或选自3-6 个碳原子的单环饱和烃基、6-12个碳原子的双环饱和烃基,其中环上的碳原子独立任选地被1-4个O、S、N或NH取代;各单环或双环任选被1、2或3个取代基取代,各取代基独立选自卤素、卤代烷基、羟基、烷基或烷氧基;
卤素为选自氟、氯、溴或碘的取代基;
卤代烷基为具有1-6个碳原子的直链或支链饱和烃基,或为具有3-6个碳原子的环状饱和烃基,或为连接具有1-6个碳原子的直链或支链饱和烃基的具有3-6个碳原子的环状饱和烃基;其中一个或多个碳原子被一个或多个卤原子取代。
2.如权利要求1所述化合物,其特征在于:式中X、Y、Z、M1、M2
各自独立地表示碳或者氮原子,当X、Y、Z、M1、M2为碳原子时,各自独立地任选被R2取代,R2是氢、烷基、氰基、卤素、卤代烷基、烷氧基、烷硫基、烷氧基烷基;
M3为碳,各自独立地任选被R4、R5取代,R4、R5为氢、氘、烷基、卤代烷基、羟基、巯基、烷氧基、烷氨基、烷硫基、烷氧基烷基、亚甲基、芳烷基、二芳基烷基、芳基或Het;
Q1是选自长度为1-8个碳原子的饱和或不饱和直链或支链烃基、芳基;
R1选自羟基、任选被一个或多个R3取代的2-氨基苯基;
R3是氢、烷基、氰基、卤素、卤代烷基、芳基或Het。
3.如权利要求1所述化合物,其特征在于:式中X、Y、Z、M1、M2
各自独立的表示碳或者氮原子,当X、Y、Z、M1、M2为碳原子时,各自独立地任选被R2取代,R2是氢、烷基、卤素、烷氧基;
M3为碳,各自独立地任选被R4、R5取代,R4、R5为氢、氘、烷基、卤代烷基、羟基、巯基、烷氧基、烷氨基、烷硫基、烷氧基烷基、亚甲基、芳烷基、二芳基烷基、芳基或Het;
Q1是选自长度为3-8个碳原子的饱和或不饱和直链或支链烃基、芳基;
R1选自羟基、任选被一个或多个R3取代的2-氨基苯基,
R3是氢、烷基、氰基、卤素、卤代烷基、芳基或Het。
4.如权利要求1所述化合物,其特征在于:所述化合物是
(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基丁酰胺(Ⅰ-1),
(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基戊酰胺(Ⅰ-2),
(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基己酰胺(Ⅰ-3),
(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基庚酰胺(Ⅰ-4),
(E)-4-(3-亚苄基-2,5-二氧代吡咯烷基)-N-羟基辛酰胺(Ⅰ-5),
(E)-N-(2-氨基-4-氟苯基)-4-(3-亚苄基-2,5-二酮吡咯烷基)丁酰胺(Ⅰ-6),
(E)-N-(2-氨基-4-氟苯基)-5-(3-亚苄基-2,5-二酮吡咯烷基)戊酰胺(Ⅰ-7),
(E)-N-(2-氨基-4-氟苯基)-6-(3-亚苄基-2,5-二酮吡咯烷基)己酰胺(Ⅰ-8),
(E)-N-(2-氨基-4-氟苯基)-7-(3-亚苄基-2,5-二酮吡咯烷基)庚酰胺(Ⅰ-9),
4-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)丁酰胺(Ⅰ-10),
5-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)戊酰胺(Ⅰ-11),
6-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)己酰胺(Ⅰ-12),
7-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)庚酰胺(Ⅰ-13),
8-(3-((E)-亚苄基)-2,5-二酮吡咯烷基)-N-((1S,2S)-2-羟基环己基)辛酰胺(Ⅰ-14)),
(E)-7-(3-(4-异丙基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-15),
(E)-7-(3-(4-二甲氨基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-16),
(E)-7-(3-(4-三氟甲基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-17),
(E)-7-(3-(4-甲基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-18),
(E)-7-(3-(2-甲基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-19),
(E)-7-(3-(2-氰基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-20),
(E)-7-(3-(2-亚甲基吡啶)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-21),
(E)-7-(3-(2-亚甲基萘基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-22),
(E)-7-(3-(2-亚甲基噻吩基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-23),
(E)-7-(3-(2-氯亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-24),
(E)-7-(3-(3-氯亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-25),
(E)-7-(3-(4-氯亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-26),
(E)-7-(3-(3-溴亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-27),
(E)-7-(3-(3-氟亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-28),
(E)-7-(3-(3-碘亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-29),
(E)-7-(3-(3,4-二氯亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-30),
(E)-7-(3-(2-甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-31),
(E)-7-(3-(3-甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-32),
(E)-7-(3-(4-甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-33),
(E)-7-(3-(3,4-二甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-34),
(E)-7-(3-(3,4,5-三甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-35),
(E)-7-(3-(4-羟基-3,5-二甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-36),
(E)-7-(3-(2-羟基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-37),
(E)-7-(3-(2-乙氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-38),
(E)-7-(3-(5-溴-2-甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-39),
(E)-7-(3-(4-溴-2-甲氧基亚苄基)-2,5-二酮吡咯烷基)-N-羟基庚酰胺(Ⅰ-40),
(E)-4-((3-亚苄基-2,5-二酮吡咯烷基)甲基)-N-羟基苯甲酰胺(Ⅰ-41)。
5.一种药物组合物,其包含权利要求 1 ~ 4 中任一项所述化合物或其药学上可接受的盐和药学上可接受的载体,其中,权利要求 1 ~ 4 中任一项所述化合物或其药学上可接受的盐为活性成分。
6.权利要求1-4任一项所述化合物在制备用于预防或治疗与HDACs有关的临床病症的药物中的用途。
7.如权利要求6所述化合物的用途,其特征在于:与HDACs有关的疾病是肺癌、黑色素瘤、肝癌、肾癌、白血病、***癌、甲状腺癌、皮肤病、胰腺癌、卵巢癌、睾丸癌、乳腺癌、膀胱癌、胆囊癌、骨髓增生异常综合症、淋巴瘤、食管癌、胃肠道癌、星型细胞瘤、神经母细胞瘤、神经胶质瘤、神经鞘瘤、间皮瘤、非胰岛素依赖型糖尿病、自身免疫性疾病。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310842593.5A CN116554079B (zh) | 2023-07-11 | 2023-07-11 | 一种组蛋白去乙酰化酶抑制剂及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310842593.5A CN116554079B (zh) | 2023-07-11 | 2023-07-11 | 一种组蛋白去乙酰化酶抑制剂及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116554079A CN116554079A (zh) | 2023-08-08 |
CN116554079B true CN116554079B (zh) | 2023-11-10 |
Family
ID=87498610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310842593.5A Active CN116554079B (zh) | 2023-07-11 | 2023-07-11 | 一种组蛋白去乙酰化酶抑制剂及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116554079B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016115360A1 (en) * | 2015-01-14 | 2016-07-21 | Coferon, Inc. | C-myc ligands capable of dimerizing in an aqueous solution, and methods of using same |
WO2022031777A2 (en) * | 2020-08-07 | 2022-02-10 | Cornell University | Therapeutically useful cure-pro molecules for e3 ligase mediated degradation of proteins, and methods of making and using them |
-
2023
- 2023-07-11 CN CN202310842593.5A patent/CN116554079B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016115360A1 (en) * | 2015-01-14 | 2016-07-21 | Coferon, Inc. | C-myc ligands capable of dimerizing in an aqueous solution, and methods of using same |
WO2022031777A2 (en) * | 2020-08-07 | 2022-02-10 | Cornell University | Therapeutically useful cure-pro molecules for e3 ligase mediated degradation of proteins, and methods of making and using them |
Also Published As
Publication number | Publication date |
---|---|
CN116554079A (zh) | 2023-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6313416B2 (ja) | Ido阻害剤 | |
TWI481597B (zh) | 組蛋白去乙醯酶(hdacs)抑制劑 | |
JP6625638B2 (ja) | Mdm2阻害薬としてのスピロピロリジン | |
CN109705071B (zh) | Hdac抑制剂及其制备方法和用途 | |
BG107889A (bg) | Тетралонови производни като антитуморни средства | |
ES2428539T9 (es) | Nuevos inhibidores de histona deacetilasas | |
JP2011500783A (ja) | ヒストンデアセチラーゼ阻害剤 | |
EP1324999A1 (fr) | Derives d'aminophenyle piperazine ou d'amino phenyle piperidine inhibiteurs de proteines prenyl transferase | |
WO2021147879A1 (zh) | Shp2抑制剂及其应用 | |
CN107200706A (zh) | 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 | |
Song et al. | Design, synthesis, and biological evaluation of (2E)-(2-oxo-1, 2-dihydro-3H-indol-3-ylidene) acetate derivatives as anti-proliferative agents through ROS-induced cell apoptosis | |
Maiereanu et al. | A novel amino-benzosuberone derivative is a picomolar inhibitor of mammalian aminopeptidase N/CD13 | |
EP3154982B1 (en) | Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction | |
Pasha et al. | Amberlyst-15 catalyzed Povarov reaction of N-arylidene-1H-indazol-6-amines and indoles: a greener approach to the synthesis of exo-1, 6, 7, 7a, 12, 12a-hexahydroindolo [3, 2-c] pyrazolo [3, 4-f] quinolines as potential sirtuin inhibitors | |
CN102260190A (zh) | 具有抗肿瘤作用的n-苯基-n′-(末端羧酸取代酰氧基)辛二酰胺类化合物及其药用盐 | |
Jin et al. | Design, synthesis and preliminary biological evaluation of indoline-2, 3-dione derivatives as novel HDAC inhibitors | |
US8445481B2 (en) | Scaffold-diversified pyrrolidinone derivatives and their use | |
CN116554079B (zh) | 一种组蛋白去乙酰化酶抑制剂及用途 | |
WO2019206120A1 (zh) | 甲酰胺类化合物、其制备方法及其应用 | |
Li et al. | Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity | |
Palluotto et al. | Synthesis and antibacterial activity of pyridazino [4, 3-b] indole-4-carboxylic acids carrying different substituents at N-2 | |
JPH04502146A (ja) | 医薬品として用いられるフェニルピロール化合物、その製造法及び用途 | |
CN111606888B (zh) | 吡咯类衍生物及其制备方法与应用 | |
Das et al. | Total synthesis and analgesic activity of 6-fluoroindan-1-carboxylic acid | |
CN108658915B (zh) | 一类含有香豆素结构的异羟肟酸类化合物、用途及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |